LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced its sponsorship of the inaugural Good Health: Mind, Body & Soul Summit, an invitation-only event scheduled for Feb. 19 at Morehouse College in Atlanta. The summit, inspired by the music and legacy of De La Soul, aims to advance health equity for Black men and families by bringing together leaders in health, culture, science, and community.
Developed in collaboration with Blacksmith holdings, the program is rooted in De La Soul's song "Good Health," written after the passing of founding member David Jolicoeur (Trugoy the Dove). The summit reflects De La Soul's evolution from musical pioneers to wellness advocates and will feature discussions on cancer, heart disease, mental health, addiction, sleep, relationships, and intergenerational wellness.
LIXTE, a clinical-stage pharmaceutical company focused on cancer drug development, said the summit aligns with its mission to connect scientific innovation with communities most impacted by health disparities. The company is advancing its first-in-class oncology compound LB-100 and its European research subsidiary, LIORA. For more details on the summit, visit https://ibn.fm/0kkqK.
LIXTE's lead compound, LB-100, is a PP2A inhibitor that has shown tolerability in cancer patients at doses associated with anti-cancer activity. According to the company, LB-100 has the potential to enhance chemotherapies and immunotherapies, improving outcomes for cancer patients. The compound is part of a new field of cancer biology called activation lethality, covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently underway for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. More information about LIXTE's research can be found at www.lixte.com.
The summit underscores the importance of addressing health disparities, particularly in Black communities, where rates of cancer, heart disease, and mental health issues are disproportionately high. By fostering dialogue between scientists, healthcare providers, and community leaders, the event aims to translate scientific advancements into tangible health benefits. LIXTE's participation highlights its commitment to not only developing innovative cancer therapies but also ensuring that these therapies reach the populations that need them most.
For the latest news and updates about LIXTE Biotechnology Holdings, visit the company's newsroom at https://ibn.fm/LIXT.
